TARS2

Across TCGA pan-cancer cohorts, TARS2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TARS2 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TARS2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TARS2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where TARS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.426	0.932	.026	10	view →
HNSC	OS	Median	All	0.626	0.800	.020	6	view →
PDAC	OS	Median	IV	0.836	0.491	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TARS2–CCRCC (OS)

Open the CCRCC breakdown →